{"id":"NCT00158756","sponsor":"GlaxoSmithKline","briefTitle":"Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants","officialTitle":"A Phase III, Partially Blind, Randomized Study to Evaluate the Immunogenicity, Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Tritanrix™-HepB and GSK Biologicals Kft's DTPw-HBV Vaccines as Compared to Concomitant Administration of Commonwealth Serum Laboratory's (CSL's) DTPw (Triple Antigen™) and GSK Biologicals' HBV (Engerix™-B), When Co-administered With GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine, to Healthy Infants at 3, 4½ and 6 Months of Age, After a Birth Dose of Hepatitis B Vaccine.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-09-12","primaryCompletion":"2006-11-01","completion":"2006-11-23","firstPosted":"2005-09-12","resultsPosted":"2017-07-12","lastUpdate":"2018-06-06"},"enrollment":308,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Hepatitis B"],"interventions":[{"type":"BIOLOGICAL","name":"Tritanrix™-HepB","otherNames":["DTPw-HBV"]},{"type":"BIOLOGICAL","name":"Rotarix™","otherNames":["HRV vaccine"]},{"type":"BIOLOGICAL","name":"Zilbrix™","otherNames":["DTPw-HBV Kft"]},{"type":"BIOLOGICAL","name":"Triple Antigen™","otherNames":["DTPwcsl vaccine"]},{"type":"BIOLOGICAL","name":"Engerix™-B","otherNames":["HBV vaccine"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tritanrix™-HepB+Rotarix™ Group","type":"EXPERIMENTAL"},{"label":"Tritanrix™-HepB+Placebo Group","type":"EXPERIMENTAL"},{"label":"Zilbrix™+Rotarix™ Group","type":"ACTIVE_COMPARATOR"},{"label":"Zilbrix™+Placebo Group","type":"ACTIVE_COMPARATOR"},{"label":"Triple Antigen™+Engerix™-B Group","type":"ACTIVE_COMPARATOR"}],"summary":"To compare the two formulations of GSK Biologicals' DTPw-HBV vaccine to concomitant administration of CSL's DTPw vaccine and GSK Biologicals' HBV with respect to the antibody response to the diphtheria antigen after a three-dose primary vaccination course.","primaryOutcome":{"measure":"Seroprotection Status for Anti-diphteria (Anti-DT) Antibodies","timeFrame":"At one month post dose 3 [PIII(M4)]","effectByArm":[{"arm":"Tritanrix-HepB+Rotarix Group","deltaMin":100,"sd":null},{"arm":"Tritanrix-HepB+Placebo Group","deltaMin":100,"sd":null},{"arm":"Zilbrix+Rotarix Group","deltaMin":100,"sd":null},{"arm":"Zilbrix+Placebo Group","deltaMin":100,"sd":null},{"arm":"Triple Antigen+Engerix-B Group","deltaMin":98.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":9,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":80},"commonTop":["Irritability","Redness","Fever","Drowsiness","Pain"]}}